Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

NCT04113616 is registered in ClinicalTrials.gov with Kartos Therapeutics, Inc. as lead sponsor.

NCT NCT04113616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04113616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
Lead sponsor
Kartos Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
September 25, 2019
Completion date
September 27, 2023
Enrollment
70 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml), secondary to myeloproliferative neoplasms (mpn), relapsed or refractory acute myeloid leukemia (aml)